Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Foresite Capital is a multi-stage venture capital firm specializing in healthcare and life sciences investments. Founded in 2011, the firm is headquartered in Los Angeles, California, with additional offices in San Francisco and New York City. Foresite Capital manages approximately $3.5 billion in assets under management (AUM) across six funds, reflecting its significant presence in the venture capital landscape.
Led by CEO and Managing Director Jim Tananbaum, a recognized figure on the Midas List, Foresite Capital employs a data science-driven approach to identify and invest in companies that leverage biology and big data to transform healthcare. The firm has achieved notable milestones, including 237 exits, with 80 of those being IPOs and 65 acquisitions, showcasing its successful track record in the industry.
Foresite Capital invests across a range of stages, from Series A to Series D and growth equity, with check sizes ranging from $50 million to $120 million. The firm maintains a balanced investment strategy, allocating 50% of its resources to early-stage companies and 50% to late-stage ventures. Their focus spans several sectors, including biotech, healthcare, drug discovery, diagnostics, digital health, and genomics.
The firm emphasizes investments in therapeutics, particularly in oncology, autoimmune diseases, and neuroscience, as well as life sciences infrastructure and precision medicine. Foresite Labs plays a crucial role in incubating early concepts, providing support from inception through to IPO, and fostering innovation through collaboration among a multidisciplinary team of scientists, engineers, and clinicians.
Foresite Capital's portfolio consists of 206 companies, reflecting a diverse range of investments in the healthcare sector. Notable companies include:
The firm has successfully facilitated 237 exits, including 80 IPOs and 65 acquisitions, underscoring its effectiveness in identifying and nurturing high-potential companies.
Jim Tananbaum: CEO & Managing Director. Jim has a distinguished background in healthcare investing and is recognized on the Midas List for his contributions to the industry.
Stella Ho: CFO & Managing Director. Stella brings extensive financial expertise to the firm, overseeing its financial operations and strategy.
Hyung Chun, MD: Partner. Hyung has a medical background and focuses on investments in therapeutics and life sciences.
Richard Lau, CFA: Partner. Richard specializes in financial analysis and investment strategy within the healthcare sector.
Vikram Bajaj, PhD: Advisor. Vikram provides scientific and technical insights to support the firm's investment decisions.
The Honorable Alex M. Azar II: Advisor. Alex brings regulatory and policy expertise, enhancing the firm's understanding of the healthcare landscape.
To pitch Foresite Capital, startups should use the preferred channel outlined on their [contact page](https://www.foresitecapital.com/contact/). The pitch deck should include a comprehensive overview of the business model, market analysis, and how the startup plans to leverage data in its operations. Response times may vary, but founders should expect a thorough review process.
Foresite Labs is a key program within Foresite Capital, dedicated to incubating early concepts in healthcare and life sciences. This program supports startups from inception through to IPO, providing resources and expertise to foster innovation. Eligibility for participation in Foresite Labs typically includes having a promising concept in the healthcare sector, with a focus on leveraging data and technology.
On February 3, 2026, Foresite Capital made its latest investment, continuing its active engagement in the healthcare sector. Recently, the firm published a blog post featuring a Q&A with Foresight Diagnostics regarding their acquisition by Natera, highlighting its ongoing involvement with portfolio companies and significant industry developments.
Q?
What are Foresite Capital's investment criteria?
A: Foresite Capital invests in companies at all stages of their life cycles, focusing on those that leverage biology and big data to transform healthcare. They emphasize sectors such as biotech, healthcare, drug discovery, diagnostics, and digital health.
Q?
How can startups apply or pitch to Foresite Capital?
A: Startups can pitch to Foresite Capital through their [contact page](https://www.foresitecapital.com/contact/). They should include a detailed presentation outlining their business model, market opportunity, and how they leverage data in their approach.
Q?
What makes Foresite Capital different from other venture firms?
A: Foresite Capital's unique value proposition lies in its multidisciplinary team of scientists, engineers, and clinicians, which allows for deep collaboration and expertise in healthcare business models.
Q?
What is the geographic scope of Foresite Capital's investments?
A: Foresite Capital primarily focuses on investments within North America, particularly in the United States.
Q?
What is the typical check size for investments?
A: Foresite Capital typically invests between $50 million and $120 million in its portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.